Acțiuni Novo Nordisk A/S (NVO) — este o companie bună?

Acțiuni Novo Nordisk A/S (NVO) — este o companie bună? — InspectStocks

Cum face bani

Sales of prescription medicines for diabetes, obesity and other conditions

Concurează cu

LLYEli Lilly and Company
A
Mărime
1,36T USD
Marjă
31,9 %

Ce vinde3

Wegovy injection
An injectable semaglutide medicine used for weight management.
Wegovy pill
A once-daily semaglutide pill used for weight management.
Ozempic
An injectable semaglutide medicine for type 2 diabetes.

Cine cumpără3

People with diabetes or obesity who obtain medicines through a prescription or buy them directly in self-pay channels.
Pharmacies and telehealth providers that supply medicines to patients.
Private insurers and public programs that cover prescription medicines, including Medicare Part D in the United States.

Pe ce se sprijină și ce l-ar putea dărâma

De ce depinde activitatea

1Recent sales growth and product launches rely on glucagon-like peptide-1 (GLP-1) medicines, including semaglutide brands such as Wegovy and Ozempic.
2Access to obesity medicines in the United States depends on insurance coverage and what patients can afford to pay themselves; the company said most Wegovy pill prescriptions there were self-pay in Q2 2026.
3Commercial supply depends on manufacturing capacity; the company said its new active pharmaceutical ingredient facilities were contributing very little commercial supply in Q2 2026.

Ce ar putea merge prost

1Competition and lower realized prices can reduce sales from obesity and diabetes medicines; the company cited intensifying United States competition and pricing pressure in Q2 2026.
2Generic versions of semaglutide can reduce sales where patent protection expires; the company reported early generic entries in some international markets.
3Cybersecurity breaches could disrupt the business.

Situațiile financiare complete →

Despre Novo Nordisk A/S

Novo Nordisk makes medicines for diabetes and obesity, including Wegovy for weight management and Ozempic for type 2 diabetes. Its medicines reach patients through healthcare providers and pharmacies, with payment coming from insurers and public health programs or directly from patients. It also develops medicines for other conditions, including rare diseases.

Sediu: Bagsværd, Denmark
Înființată în: 1923
Angajați: around 66,700 (Q2 2026, medium)
Listată la: New York Stock Exchange
Sfârșitul exercițiului financiar: December 31

Construit din raportările proprii ale Novo Nordisk A/S la Comisia pentru Valori Mobiliare și Burse a SUA (SEC). Cifrele sunt cele raportate, iar istoricul pe acțiune este recalculat la baza de acțiuni de azi. Această companie raportează în DKK. Cifrele sunt convertite în dolari la 1,00 USD = 6,7640 DKK, cursul actual, aplicat la fel tuturor perioadelor — astfel creșterea și marjele îi aparțin companiei, nu cursului valutar. Aceasta descrie o afacere — nu este consultanță de investiții și nu este o recomandare de cumpărare sau vânzare.

Keep exploring

The themes Novo Nordisk A/S is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Highest-graded in Drug Manufacturers General

Graded A or B and worth $2B or more: A first, then the largest.

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

Cum face bani

Sales of prescription medicines for diabetes, obesity and other conditions

Concurează cu

LLYEli Lilly and Company
A
Mărime
1,36T USD
Marjă
31,9 %

Ce vinde3

Wegovy injection
An injectable semaglutide medicine used for weight management.
Wegovy pill
A once-daily semaglutide pill used for weight management.
Ozempic
An injectable semaglutide medicine for type 2 diabetes.

Cine cumpără3

People with diabetes or obesity who obtain medicines through a prescription or buy them directly in self-pay channels.
Pharmacies and telehealth providers that supply medicines to patients.
Private insurers and public programs that cover prescription medicines, including Medicare Part D in the United States.

Pe ce se sprijină și ce l-ar putea dărâma

De ce depinde activitatea

1Recent sales growth and product launches rely on glucagon-like peptide-1 (GLP-1) medicines, including semaglutide brands such as Wegovy and Ozempic.
2Access to obesity medicines in the United States depends on insurance coverage and what patients can afford to pay themselves; the company said most Wegovy pill prescriptions there were self-pay in Q2 2026.
3Commercial supply depends on manufacturing capacity; the company said its new active pharmaceutical ingredient facilities were contributing very little commercial supply in Q2 2026.

Ce ar putea merge prost

1Competition and lower realized prices can reduce sales from obesity and diabetes medicines; the company cited intensifying United States competition and pricing pressure in Q2 2026.
2Generic versions of semaglutide can reduce sales where patent protection expires; the company reported early generic entries in some international markets.
3Cybersecurity breaches could disrupt the business.

Situațiile financiare complete →

Despre Novo Nordisk A/S

Sediu: Bagsværd, Denmark
Înființată în: 1923
Angajați: around 66,700 (Q2 2026, medium)
Listată la: New York Stock Exchange
Sfârșitul exercițiului financiar: December 31

Cum face bani

Concurează cu

Ce vinde3

Cine cumpără3

Pe ce se sprijină și ce l-ar putea dărâma

De ce depinde activitatea

Ce ar putea merge prost

Despre Novo Nordisk A/S

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Cum face bani

Concurează cu

Ce vinde3

Cine cumpără3

Pe ce se sprijină și ce l-ar putea dărâma

De ce depinde activitatea

Ce ar putea merge prost

Despre Novo Nordisk A/S

Novo Nordisk A/S

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Big pharma

Creștere și numerar — 3 din 5

Tendința afacerii

Prețul acțiunii și nota în timp

Cum face bani

Concurează cu

Ce vinde3

Cine cumpără3

Pe ce se sprijină și ce l-ar putea dărâma

De ce depinde activitatea

Ce ar putea merge prost

Despre Novo Nordisk A/S

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Cum face bani

Concurează cu

Ce vinde3

Cine cumpără3

Pe ce se sprijină și ce l-ar putea dărâma

De ce depinde activitatea

Ce ar putea merge prost

Despre Novo Nordisk A/S

Novo Nordisk A/S

Evoluția din trecut

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Big pharma

Creștere și numerar — 3 din 5

Tendința afacerii

Prețul acțiunii și nota în timp